Andrew Sinclair - Net Worth and Insider Trading

Andrew Sinclair Net Worth

The estimated net worth of Andrew Sinclair is at least $114 Million dollars as of 2024-11-13. Andrew Sinclair is the Director of Sierra Oncology Inc and owns about 1,314,127 shares of Sierra Oncology Inc (SRRA) stock worth over $72 Million. Andrew Sinclair is the Director of Soleno Therapeutics Inc and owns about 686,840 shares of Soleno Therapeutics Inc (SLNO) stock worth over $39 Million. Andrew Sinclair is also the Director of Adicet Bio Inc and owns about 2,140,721 shares of Adicet Bio Inc (ACET) stock worth over $3 Million. Details can be seen in Andrew Sinclair's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Andrew Sinclair has not made any transactions after 2022-01-31 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Andrew Sinclair

To

Andrew Sinclair Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Andrew Sinclair owns 4 companies in total, including Soleno Therapeutics Inc (SLNO) , Sierra Oncology Inc (SRRA) , and Verona Pharma PLC (VRNA) among others .

Click here to see the complete history of Andrew Sinclair’s form 4 insider trades.

Insider Ownership Summary of Andrew Sinclair

Ticker Comapny Transaction Date Type of Owner
SLNO Soleno Therapeutics Inc 2020-06-26 director
SRRA Sierra Oncology Inc 2022-01-31 director
VRNA Verona Pharma PLC 2021-01-01 director
LIMIT LIMIT 2021-12-08 director

Andrew Sinclair Latest Holdings Summary

Andrew Sinclair currently owns a total of 3 stocks. Among these stocks, Andrew Sinclair owns 1,314,127 shares of Sierra Oncology Inc (SRRA) as of January 31, 2022, with a value of $72 Million and a weighting of 63.28%. Andrew Sinclair owns 686,840 shares of Soleno Therapeutics Inc (SLNO) as of June 26, 2020, with a value of $39 Million and a weighting of 34.47%. Andrew Sinclair also owns 2,140,721 shares of Adicet Bio Inc (ACET) as of December 8, 2021, with a value of $3 Million and a weighting of 2.25%.

Latest Holdings of Andrew Sinclair

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
SRRA Sierra Oncology Inc 2022-01-31 1,314,127 54.99 72,263,844
SLNO Soleno Therapeutics Inc 2020-06-26 686,840 57.31 39,362,800
ACET Adicet Bio Inc 2021-12-08 2,140,721 1.20 2,568,865

Holding Weightings of Andrew Sinclair


Andrew Sinclair Form 4 Trading Tracker

According to the SEC Form 4 filings, Andrew Sinclair has made a total of 1 transactions in Sierra Oncology Inc (SRRA) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Sierra Oncology Inc is the acquisition of 150,000 shares on January 31, 2022, which cost Andrew Sinclair around $4 Million.

According to the SEC Form 4 filings, Andrew Sinclair has made a total of 1 transactions in Soleno Therapeutics Inc (SLNO) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Soleno Therapeutics Inc is the acquisition of 222,222 shares on June 26, 2020, which cost Andrew Sinclair around $5 Million.

According to the SEC Form 4 filings, Andrew Sinclair has made a total of 2 transactions in Adicet Bio Inc (ACET) over the past 5 years, including 2 buys and 0 sells. The most-recent trade in Adicet Bio Inc is the acquisition of 500,000 shares on December 8, 2021, which cost Andrew Sinclair around $7 Million.

Insider Trading History of Andrew Sinclair

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Andrew Sinclair Trading Performance

GuruFocus tracks the stock performance after each of Andrew Sinclair's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Andrew Sinclair is 48.8%. GuruFocus also compares Andrew Sinclair's trading performance to market benchmark return within the same time period. The performance of stocks bought by Andrew Sinclair within 3 months outperforms 3 times out of 6 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Andrew Sinclair's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Andrew Sinclair

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
4 out of 5 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 6.77 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 3.99 LIMIT LIMIT LIMIT LIMIT LIMIT

Andrew Sinclair Ownership Network

Ownership Network List of Andrew Sinclair

No Data

Ownership Network Relation of Andrew Sinclair

Insider Network Chart

Andrew Sinclair Owned Company Details

What does Soleno Therapeutics Inc do?

Who are the key executives at Soleno Therapeutics Inc?

Andrew Sinclair is the director of Soleno Therapeutics Inc. Other key executives at Soleno Therapeutics Inc include See Remarks Patricia C Hirano , See Remarks Kristen Yen , and director & See Remarks Bhatnagar Anish .

Soleno Therapeutics Inc (SLNO) Insider Trades Summary

Over the past 18 months, Andrew Sinclair made no insider transaction in Soleno Therapeutics Inc (SLNO). Other recent insider transactions involving Soleno Therapeutics Inc (SLNO) include a net sale of 479,373 shares made by Bhatnagar Anish , a net sale of 79,014 shares made by Kristen Yen , and a net sale of 47,490 shares made by Patricia C Hirano .

In summary, during the past 3 months, insiders sold 1,210,871 shares of Soleno Therapeutics Inc (SLNO) in total and bought 0 shares, with a net sale of 1,210,871 shares. During the past 18 months, 2,825,824 shares of Soleno Therapeutics Inc (SLNO) were sold and 1,210,087 shares were bought by its insiders, resulting in a net sale of 1,615,737 shares.

Soleno Therapeutics Inc (SLNO)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Soleno Therapeutics Inc Insider Transactions

No Available Data

Andrew Sinclair Mailing Address

Above is the net worth, insider trading, and ownership report for Andrew Sinclair. You might contact Andrew Sinclair via mailing address: C/o Soleno Therapeutics Inc., 1235 Radio Road, Suite 110, Redwood City Ca 94065.